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2013.01.0Abstract Background: Distinguishing endocervical adenocarcinoma (ECA) from endometrial
adenocarcinoma (EMA) is clinically signiﬁcant and cannot always be made on the basis of mor-
phology alone or clinical ﬁndings.
The aim of this study was to study the potential utility of ProExC as a new marker for cervical ade-
nocarcinoma, and to evaluate a panel of monoclonal antibodies composed of p16, ER, PR, and
vimentin, and assess their diagnostic value in distinguishing between ECA and EMA.
Methods: Immunohistochemistry using monoclonal antibodies to ProExC, p16, estrogen receptor
(ER), progesterone receptor (PR), and vimentin, was performed to examine 30 cases, including 10
ECAs and 20 EMAs.
Results: Eight out of 10 cases (80%) of ECA were positive for ProExC, whereas only 2 cases of
EMA (10%) were positive. The difference of ProExC expression in the two groups of malignancy
was statistically signiﬁcant (p= 0.003). P16 was positive in 8 cases (80%) of ECAs and in 4 cases
(20%) of EMAs. Estrogen receptor was negative in all cases of ECA, while it was positive in 95% of
EMA. Progesterone receptor was positive in 2 cases (20%) of ECA and in 16 cases (80%) of EMA.
Vimentin was positive in only one case (10%) of ECA, and in 16 cases (80%) of EMA.
Conclusion: ProExC is a novel immunohistochemical marker for differentiating ECA from EMA
and its inclusion in a panel of immunohistochemical markers including p16, ER, PR, and vimentin
is recommended when there is morphological and clinical doubt as to the primary site of endocer-
vical or endometrial origin.
ª 2013 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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05Introduction
In Egypt, current estimates indicate that every year, 514 wo-
men are diagnosed with cervical cancer and 299 die from the
disease. Cervical cancer ranks as the 14th most frequent cancer
among women in Egypt, and the 12th most frequent cancerand hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
88 G.E. Eshebaamong women between 15 and 44 years of age [1]. About
10.3% of women in the general population are estimated to
harbor cervical HPV infection at a given time. Human papillo-
mavirus (HPV) infection contributes to nearly most of the
cases of cervical cancer based on the observed presence of
HPV DNA within these cancers [2] and more than half of
the HPV-associated cervical cancers are attributed to infection
with HPV16 [2–4].
Morphologic distinction of endocervical adenocarcinoma
from its endometrial counterpart is clinically signiﬁcant due
to their differences in management and prognosis [5]. The
treatment of endometrial carcinoma begins with surgical stag-
ing and intraoperative assessment of the grade and extent of
tumor in the uterus while primary endocervical carcinoma is
managed by an initial radical hysterectomy and pelvic lym-
phadenectomy with or without adjuvant radiotherapy [5–7].
The differential diagnosis between the two gynecologic neo-
plasms can be problematic especially when the tumor involves
the lower uterine segment or upper endocervix [5]. Histologic
features that favor endocervical origin include eosinophilic ﬁ-
brotic stroma, apical mitotic ﬁgures, basal apoptotic bodies,
presence of adenocarcinoma in situ or squamous dysplasia,
and monomorphous appearance. Features that favor endome-
trial origin include the presence of endometrial stromal or
foam cells, complex endometrial hyperplasia, and polymor-
phous appearance [8].
Before the identiﬁcation of HPV as a probable etiologic
agent in the development of endocervical adenocarcinomas
and the advent of commercially available markers for detecting
HPV, most of the immunohistochemical markers used; such as
estrogen and progesterone receptors and vimentin, targeted
endometrial adenocarcinomas. Carcinoembryonic antigen
(CEA) was the only positive marker for endocervical adeno-
carcinomas. However, the use of CEA is signiﬁcantly limited
by the high degree of variability in results depending on the
methodology and antibody used [9].
Recent studies have investigated the role of HPV in endo-
cervical adenocarcinomas by using HPV ISH or p16 to identify
the presence of high-risk HPV. The p16INK4a (cyclin-depen-
dent kinase inhibitor 4) is a tumor suppressor protein that
binds to cyclin–cdk4/6 complexes, which blocks kinase activity
and inhibits progression to the S phase of the cell cycle in the
nucleus. Over-expression of p16 has been observed in high-
grade CINs and carcinomas and, therefore, has been used as
a surrogate marker and a useful addition to the panel for the
differential diagnosis between endocervical and endometrial
primaries [2,3,10–14]. Similar to p16, ProExC has been re-
cently proposed as an additional marker for HPV related can-
cer cervix. Recent studies have demonstrated that ProExC
targets cell cycle proteins, minichromosome maintenance pro-
tein-2 (MCM2), and topoisomerase II-a (TOP2A) [15,16].
MCM2 is a member of the DNA licensing factor family and
a cell proliferation marker. TOP2A is an enzyme that unknots
DNA for DNA replication, transcription, chromosome segre-
gation, and cell cycle progression. Both MCM2 and TOP2A
have been shown to be over-expressed when viral DNA inte-
grates into the host genome leading to increased levels of E6
and E7 and aberrant S-phase induction [8,17–23].
High-risk human papillomaviruses (HPV) encode two
oncogenes, E6 and E7 and their integration into the host
DNA causes their increased expression and the development
of cervical cancers [19–24].The E6 protein consists of 158 amino acid residues and con-
tains two zinc-ﬁnger binding motifs. The E6 protein stimulates
cell proliferation by promoting degradation of the tumor sup-
pressor p53. Such E6-stimulated degradation interferes with
biological functions of p53; thus disrupting the control of cell
cycle progression, leading ﬁnally to increased tumor cell
growth [25].
E7 is a multifunctional protein known for its ability to inac-
tivate the tumor suppressor pRb. E7 binds to more than 20 cel-
lular proteins [24]. The most well characterized target of E7 is
the retinoblastoma tumor suppressor, Rb [24,25].
E7 binds to a region of the Rb protein called the ‘pocket
domains’. The ‘pocket domain’ sequences of Rb are essential
for its tumor suppressor function. One of the major biochem-
ical functions of Rb is to bind E2F-family transcription factors
and inhibit the expressions of replication enzyme genes. E7 dis-
rupts the interaction between Rb and E2F, resulting in the re-
lease of E2F factors in their transcriptionally active forms.
Furthermore, E7 modulates E2F activity by other mecha-
nisms; E7 also inhibits the cyclin-dependent kinase (cdk) inhib-
itors p21 and p27, and may directly activate both cyclin A/
cdk2 and E2F1 [25].
Various studies in the literature have investigated the
expression of ProExC in different tissues and organs. For
example, Chen et al. described that ProExC is a useful prolif-
eration marker for high-grade VIN [26].
While Bhandarkar et al. reported that ProExC stains posi-
tive in recurrent respiratory papilloma (RRP) and the authors
suggested that further studies are necessary to determine
whether ProExC can be used in the triage of cases of clinically
aggressive RRP for closer follow-up or frequent operative
intervention [27].
Similarly, Sa´nchez-Herna´ndez et al. found that ProExC was
observed in the whole epidermis thickness in 86.5% of Bowen’s
disease [28].
Walts et al. observed positive staining for ProExC in Paget
cells in all of the 26 cases of Paget’s disease irrespective of the
tissue site (extramammary, mammary) and in melanoma cells
in all of the 12 cases of primary perineal melanoma [29].Materials and methods
Formalin-ﬁxed, parafﬁn-embedded tissue blocks containing
adenocarcinomas of endocervix and endometrium were ob-
tained retrospectively from the archives of the Department
of Pathology, Faculty of Medicine, Tanta University during
the period between 2005 and 2010. Only primary endocervical
and endometrial adenocarcinomas from hysterectomy or con-
ization specimens with negative hysteroscopy were included in
this work. Small biopsy specimens were excluded from the
study.
The study group consisted of 20 cases of EMA and 10 cases
ECA. The endometrial adenocarcinoma cases were classiﬁed
as follows: 16 cases were endometrioid adenocarcinoma and
4 cases were serous adenocarcinoma. On the other hand, the
ECA included: 8 endocervical mucinous adenocarcinoma and
2 cases of endocervical endometrioid adenocarcinoma.
Immunohistochemical analysis was done with the following
commercially available antibodies: ProExC, p16, ER, PR, and
vimentin. The characteristics of antibodies used for evaluation
were summarized in Table 1.
Table 1 Characteristics of antibodies used for evaluation.
Antibody Clone Source Dilution
ProExC MCM2 26H6.19 BD Predilute
P16 E6H4 DAKO, Carpinteria, CA 1:25
Vim Vim3B4 DAKO, Carpinteria, CA 1:200
ER 1D5 DAKO, Carpinteria, CA 1:80
PR PgR636 DAKO, Carpinteria, CA 1:80
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embedded blocks then deparafﬁnized in xylene, and hydrated
in graded alcohols. Immunostaining was performed with the
Dako Autostainer. The slides were incubated with peroxi-
dase-blocking reagent, followed by the primary antibody then
the visualization reagent (secondary goat-antimouse immuno-
globulin and horseradish peroxidase linked to a dextran poly-
mer backbone). After rinsing with distilled water, the slides
were incubated with DAB (3, 3-diaminobenzidine) substrate–
chromagen solution and a Mayer hematoxylin counter stain
was applied before cover slipping.
Scoring methods
For ER, PR and, vimentin; the staining was scored as strong
(2), weak (1), or negative (0). Nuclear staining was scored as
positive for ER and PR; while membranous and/or cytoplas-
mic staining was considered positive for vimentin. For ProExC
and p16, the staining was scored as diffuse (>80%) strong (2),
focal (5% to 80%) strong (1), or negative (0) based on the nu-
clear staining for ProExC and nuclear staining with or without
cytoplasmic staining for p16. For ProExC and p16, weak cyto-
plasmic staining or reactivity in <5% nuclei was interpreted as
negative [8].
Statistical analysis
Descriptive analysis was performed to evaluate the frequencies
and distributions of the analytic variables. Fisher’s exact test
was used to test the difference of each immunohistochemical
biomarker between patients with endocervical and endometrial
tumors. P values were reported. All tests were 2-sided and the
signiﬁcance level was 0.05. All analyses were performed using
SPSS statistical software (SPSS Inc., Chicago, IL).
Results
A total of 30 cases were studied in this work; the cases in-
cluded: 20 cases of EMAs and 10 cases of ECAs.
The endometrial adenocarcinoma cases were: 16 cases of
endometrioid adenocarcinoma (Fig. 2(A)) and 4 cases were
of serous adenocarcinoma.
On the other hand, the ECA included: 8 endocervical
mucinous adenocarcinoma and 2 cases of endocervical endo-
metrioid adenocarcinoma (Fig. 1(A)).
Immunohistochemical ﬁndings
The detailed immunohistochemical characteristics that were
observed in ECA and EMA using ProExC, p16, ER, PR,and vimentin were summarized in Table 2 and were shown
in Figs. 1 and 2.
Positive nuclear staining for ProExC was observed in 80%
(8/10) of endocervical adenocarcinoma cases. On the other
hand, it was present in only 2 cases (10%) of endometrial ade-
nocarcinoma (Fig. 2(D)). The difference of ProExC expression
in the two groups of gynecological malignancy was statistically
signiﬁcant (p= 0.003). In ECA cases, 6 out of 8 cases of
mucinous adenocarcinoma were positive for ProExC; 5 had
score 2 (diffuse (>80%) strong), while the remaining case
showed score 1 (focal (5% to 80%) strong). Both cases of
endometrioid adenocarcinoma of the cervix demonstrated
score 2 (Fig. 1(B)).
The two cases of EMA that were positive for ProExC had
score 1 and were serous adenocarcinoma of the uterus.
For evaluation of p16 immunohistochemistry, nuclear and
cytoplasmic staining were taken into consideration. The p16
expression in ECAs was observed in all but 2 cases (80%).
The expression pattern of p16 in ECA was as follows: 7 out
of 8 cases of mucinous adenocarcinoma were positive for
p16; 4 had score 2, while the remaining 3 cases showed score
1. One out of 2 cases of endometrioid adenocarcinoma of
the cervix was negative for p16, while the second case exhibited
score 2 (Fig. 1(C)).
On the other hand, the p16 expression in EMAs was re-
stricted to only 4 cases (20%), and was also observed both
in nuclei and cytoplasm with varying degrees of staining
intensity and extents. The difference of p16 expression in
EMA and ECA was statistically signiﬁcant (p= 0.004)
(Table 1).
Three cases of serous adenocarcinoma of the uterus were
positive and had score 1, while the remaining case was endo-
metrioid carcinoma and also exhibited score 1. In general,
p16 was diffuse in ECA and patchy in EMA.
Regarding the hormone receptors, ER was not detected
in any of the ECA cases (Fig. 1(D)), while it was positive
in 19 cases (95%) of EMA (Fig. 2(B)). The single nega-
tive case for ER was a serous adenocarcinoma of the
endometrium.
On the other hand, PR was detected in 16 out of 20 cases
(80%) of EMA, while it was positive in only two cases
(20%) of cervical mucinous adenocarcinoma. Three out of 4
serous adenocarcinoma of the endometrium were negative
for PR and one case of the usual endometrioid adenocarci-
noma was negative for PR.
A statistically signiﬁcant difference of ER and PR expres-
sions in EMA and ECA was found as (p< 0.001) and
(p= 0.004) respectively.
Vimentin was positive in 1 case (10%) of ECA, and in 16
out of 20 (80%) EMA (Fig. 2(C)). All cases of serous adeno-
carcinoma of the endometrium were negative for vimentin.
Figure 1 (A) Endocervical adenocarcinoma, endometrioid type, note the normal squamous epithelium of the cervix in the right lower
corner (·40). (B) Diffuse strong ProExC (·100). (C) Diffuse strong p16 (·100). (D) Negative estrogen receptor (·100). This case also
showed negative progesterone receptor and vimentin (not shown).
Figure 2 (A) Endometrial adenocarcinoma, endometrioid type (·40). (B) Positive estrogen receptor (·40). (C) Positive vimentin (·200).
(D) Scattered weak nuclear ProExC staining which was considered as negative (·100). This case demonstrated positive progesterone
receptor and negative p16 (not shown).
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The histomorphologic overlap of ECA and EMA can make dif-
ferentiation difﬁcult on H&E in small pre-operative biopsy orcuretting specimens. The distinction between the two gyneco-
logical malignancies is very important in guiding treatment [30].
Recently, ProExC was introduced as a new marker for cer-
vical dysplasia and neoplasia [17–23].
Table 2 Expression pattern of ProExC, p16, ER, PR, and vimentin among ECA and EMA.
Endocervical adenocarcinoma (ECA) Endometrial adenocarcinoma (EMA) P-value
Scoring of immunoreactivity Scoring of immunoreactivity
No. (%) 0 +1 +2 No. (%) 0 +1 +2
ProExCa 8/10 80 2 1 7 2/20 10 18 2 0 0.003*
p16b 8/10 80 2 3 5 4/20 20 16 4 0 0.004*
ERa 0/10 0 10 0 0 19/20 95 1 1 18 <0.001*
PRa 2/10 20 8 1 1 16/20 80 4 2 14 0.004*
Vimentinc 1/10 10 9 1 0 16/20 80 4 10 6 0.004*
 P-value (the difference in positive immunoreactivity between ECA and EMA as calculated by Fisher’s exact test).* Signiﬁcant value.
a Nuclear staining was scored as positive for ProExC, ER and PR.
b Nuclear staining with or without cytoplasmic staining was scored as positive for p16.
c Membranous and/or cytoplasmic staining was considered positive for vimentin.
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exhibited positive nuclear staining for ProExC. On the other
hand, only 10% of endometrial adenocarcinoma showed such
positivity. Similar results were obtained by Aximu [22].
The 2 ProExC negative cervical adenocarcinoma cases, in
this work, were of the mucinous type. On the other hand,
the 2 cases of EMA that were ProExC positive were serous
adenocarcinoma and both cases exhibited score 1 positivity
for ProExC.
In this study, nuclear and cytoplasmic p16 immunostaining
were seen in 80% of ECA, while it was positive in 20% of
EMA. These results were in keeping with the published data
which have shown that p16 immunostaining has a high sensi-
tivity for endocervical carcinoma (range 82–100%), supporting
the belief that p16 can be used as a biomarker for ECA [13,14].
ProExC, in this study, was as sensitive as p16 in detecting
ECA; however, it was more speciﬁc than p16. Guo reported
that ProExC was more sensitive than p16 in detecting ECA
as ProExC was positive in 93% (27/29) of ECA cases while
p16 was over-expressed in 90% (26/29) of ECA cases [15].
There are various quantitative scoring mechanisms of
p16INK4a expression using various cut-off thresholds in the
literature.
Kong deﬁned the cut-off point for p16INK4a expression to
be 5%cells stained positively [8].Khoury used the positive stain-
ing area >50% as a cut-off [5]. They all took both nucleic and
cytoplasmic p16 staining into consideration. McCluggage re-
ported that a diffuse, strong staining pattern of p16INK4a,
involving nearly all tumor cells tends to be an ECA, whereas, fo-
cal, patchy staining pattern of p16 involving 0–50% of cells
tends to be an EMA in routine whole-sectioned tissue slides [10].
In this work, weak nuclear and/or cytoplasmic staining or
reactivity in, <5% nuclei was interpreted as negative for Pro-
ExC and p16 according to Kong [8].
In this work, it was found, as others did [8,10], that 20% of
ECAs were completely negative for ProExC and/or p16. One
case of mucinous adenocarcinoma of the cervix was negative
for both markers. The explanations for these results were un-
clear. It was either due to technical failure or as a result of
HPV-independent mechanisms [10]. Odida reported that
25% of ECA were negative for p16. Moreover, the latter
author found that the HPV negative cervical ECA showed
an over-expression of p16, and the author attributed this ﬁnd-
ing to the possibility of HPV-independent mechanisms of p16
over-expression in some cervical ECA [31].It was not clear why ProExC or p16 expression was present
in some cases of EMA. One explanation was that this positiv-
ity was a result of HPV-independent mechanisms [8,11].
Ansari-Lari tested HPV in situ hybridization and p16 immuno-
staining in 24 EMAs. The authors found that despite HPV was
not detected in any case of EMA examined, moderate or
strong p16 staining in 50% of tumor cells was detected in
25% of the cases [11]. On the contrary, previous studies have
identiﬁed HPV subtypes in a minority of endometrial adeno-
carcinomas [32–34].
In this work, ER was positive in 95% of EMA while it was
completely absent in ECA. On the other hand, PR was positive
in 80% of EMA and in 20% of ECA. Vimentin was positive in
1 out of 10 cases (20%) of ECA, while it was detected in 16 out
of 20 cases (80%) of EMA, (p= 0.004).
The 4 cases of serous adenocarcinoma of the endometrium
showed the following proﬁles: ER was positive in 3/4 cases, PR
was positive in 1/4 cases, while vimentin was negative in all
cases.
Surprisingly, in this study, some cases of uterine serous car-
cinoma demonstrated focal strong staining for p16 (3/4, 75%)
and ProExC (2/4, 50%) and less ER, PR, and vimentin expres-
sion than the usual endometrioid adenocarcinoma. Therefore,
it is important to recognize their speciﬁc morphological pat-
tern to avoid misdiagnosis as an endocervical primary based
on strong p16 reactivity or strong ProExC. These data were
partially concordant with those of Kong. The latter author re-
ported that uterine serous carcinoma frequently exhibited dif-
fuse strong reactivity for p16 (7/13, 53.8%) and ProExC (8/13,
61.5%) [8].
Prior studies also have reported diffuse strong p16 in uter-
ine serous carcinomas (100%) [12,35] however, these studies
did not comment on ProExC in serous carcinomas.
Conﬂicting observations on the sensitivity of vimentin in
EMA and ECA have been reported. Khoury reported that
vimentin was positive in 1 of 14 (7%) ECA, and 9 of 18
(50%) EMA [5], while McCluggage found that vimentin was
detected in 29/30 (96.7%) of EMA, and in 2/26 (7.7%) of
ECA [10].
Cervical biopsy, used in conjunction with Pap cytology test-
ing, human papillomavirus (HPV) DNA testing, and colpos-
copy, has an important role in the evaluation and
management of patients with cervical dysplastic lesions, which
is important for the prevention and early detection of cervical
cancer [36]. According to the guidelines of the American
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men with cervical biopsy – conﬁrmed cervical intraepithelial
neoplasia (CIN) 2/3 should undergo an excisional treatment,
such as loop electrosurgical excision procedure, or conization
[36]. Although these treatments are sufﬁcient in eliminating
cervical precancerous lesions and, thus, in preventing cervical
cancer, they also have been associated with pregnancy compli-
cations, such as cervical stenosis or incompetence, especially in
young women [37].
Therefore, it is critical to ensure that cervical biopsy and Pap
cytology results are interpreted accurately to avoid unnecessary
treatment. In practice, the accurate interpretation of cervical
biopsy and Pap cytology results may be complicated by various
factors such as inﬂammation, presence of immature squamous
metaplasia, treatment effect, and atrophy. Furthermore, the
diagnostic consistency of cervical biopsy and Pap cytology is
usually low owing to intra-observer and inter-observer variabil-
ity and poor reproducibility [36]. Therefore, there is a strong
demand for additional, more sensitive and speciﬁc markers to
improve screening programs. The use of biomarkers such as
p16 and ProExC has been reported to facilitate the detection
of potentially abnormal cells on a background of normal, reac-
tive or other nonmalignant cells within a Pap cytology sample
based upon simple immunocytochemistry [38].
Similarly, p16 and ProExC immunostains demonstrated the
highest speciﬁcity for the detection of CIN 2+ and CIN 3+
and for distinguishing CIN 3 from mild cervical dysplasia or
non-dysplastic cervical lesions in cervical biopsies [15]. Thus,
their use to select women truly at risk of lesion progression
and in need of necessary treatment could lead to cost savings
and eliminate patient anxiety [38].
Conclusion
Highly speciﬁc biomarker, such as ProExC, has the potential
for improving the diagnostic accuracy in differentiating be-
tween ECA and EMA.
Based on the above mentioned data, the optimal approach
to distinguish between ECA and EMA would be to use a 3
marker panel of an HPV marker (ProExC or p16), a hormone
receptor marker (ER or PR), and vimentin.
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